EZHIP and central nervous system neoplasm: In addition to the K27M status, other changes, such as the overexpression of EZHIP and alterations in the epidermal growth factor receptor (EGFR), have been reported, which were recently included in the latest 2021 WHO classification of CNS tumors as “H3K27-altered tumors” [6].